undamentalytics Newsletter
Sign in

Absci Corp income statement

In fiscal 2025, Absci Corp reported revenue of $2.8m, down 38.2% on the year before, operating income of −$120m (a -4297.0% margin) and net income of −$115m, or −$0.84 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue5566532
Research and development11455948648186
Selling, general and administrative6294138363535
Operating income−13−75−107−116−109−120−126
Interest expense1311100
Income before tax−14−110−105−110−103−115−121
Income tax0−9−00000
Net income−14−101−105−111−103−115−121
Diluted EPS−$3.19−$2.08−$1.15−$1.20−$0.94−$0.84−$0.80
Diluted shares (average)15m50m91m92m110m137m151m
EBITDA−12−69−94−102−95−109−115

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABSI vs OVIDABSI vs RNACABSI vs DAREABSI vs MCRB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Absci Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Absci Corp.